These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 25787234)

  • 21. Two birds that exclude each other: the Renbök phenomenon.
    Mirmirani P
    J Invest Dermatol; 2015 Apr; 135(4):1180. PubMed ID: 25431848
    [No Abstract]   [Full Text] [Related]  

  • 22. Serum Human Beta-Defensin-2 Is a Possible Biomarker for Monitoring Response to JAK Inhibitor in Psoriasis Patients.
    Jin T; Sun Z; Chen X; Wang Y; Li R; Ji S; Zhao Y
    Dermatology; 2017; 233(2-3):164-169. PubMed ID: 28654918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Do we need more psoriasis therapies?
    Lebwohl M
    Lancet; 2015 Aug; 386(9993):512-4. PubMed ID: 26051367
    [No Abstract]   [Full Text] [Related]  

  • 24. Quantitative Evaluations of Time-Course and Treatment Effects of Systemic Agents for Psoriasis: A Model-Based Meta-Analysis.
    Checchio T; Ahadieh S; Gupta P; Mandema J; Puig L; Wolk R; Valdez H; Tan H; Krishnaswami S; Tallman A; Kaur M; Ito K
    Clin Pharmacol Ther; 2017 Dec; 102(6):1006-1016. PubMed ID: 28480503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman.
    Mrowietz U; Gerdes S; Gläser R; Schröder O
    Acta Derm Venereol; 2017 Feb; 97(2):283-284. PubMed ID: 27349217
    [No Abstract]   [Full Text] [Related]  

  • 26. [Tofacitinib].
    Döker S; Dewenter M; El-Armouche A
    Dtsch Med Wochenschr; 2014 May; 139(19):1003-8. PubMed ID: 24782154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Case Report Highlighting the Effective Treatment of Alopecia Universalis With Tofacitinib in an Adolescent and Adult Patient.
    Patel NU; Oussedik E; Grammenos A; Pichardo-Geisinger R
    J Cutan Med Surg; 2018; 22(4):439-442. PubMed ID: 29463114
    [No Abstract]   [Full Text] [Related]  

  • 28. Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.
    Yiu ZZ; Warren RB
    Am J Clin Dermatol; 2016 Jun; 17(3):191-200. PubMed ID: 26923915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tofacitinib in kidney transplantation.
    Wojciechowski D; Vincenti F
    Expert Opin Investig Drugs; 2013 Sep; 22(9):1193-9. PubMed ID: 23841583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Janus kinase inhibitor tofacitinib is a potential therapeutic option for refractory eosinophilic fasciitis.
    Cao XY; Zhao JL; Hou Y; Wang FD; Lu ZH
    Clin Exp Rheumatol; 2020; 38(3):567-568. PubMed ID: 31820721
    [No Abstract]   [Full Text] [Related]  

  • 31. Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis.
    Dhayalan A; King BA
    JAMA Dermatol; 2016 Apr; 152(4):492-3. PubMed ID: 26630079
    [No Abstract]   [Full Text] [Related]  

  • 32. Reversal of Alopecia Universalis by Tofacitinib: A Case Report.
    Scheinberg M; Ferreira SB
    Ann Intern Med; 2016 Nov; 165(10):750-751. PubMed ID: 27842401
    [No Abstract]   [Full Text] [Related]  

  • 33. Tofacitinib as a novel salvage therapy for refractory T-cell large granular lymphocytic leukemia.
    Bilori B; Thota S; Clemente MJ; Patel B; Jerez A; Afable Ii M; Maciejewski JP
    Leukemia; 2015 Dec; 29(12):2427-9. PubMed ID: 26449659
    [No Abstract]   [Full Text] [Related]  

  • 34. Successful hair regrowth in a Korean patient with alopecia universalis following tofacitinib treatment.
    Kim BY; Kim HS
    Singapore Med J; 2017 May; 58(5):279-280. PubMed ID: 28536724
    [No Abstract]   [Full Text] [Related]  

  • 35. Current and future oral systemic therapies for psoriasis.
    Kelly JB; Foley P; Strober BE
    Dermatol Clin; 2015 Jan; 33(1):91-109. PubMed ID: 25412786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.
    Tanaka Y; Yamaoka K
    Mod Rheumatol; 2013 May; 23(3):415-24. PubMed ID: 23212593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic development in psoriasis.
    Sobell JM; Leonardi CL
    Semin Cutan Med Surg; 2014 Jun; 33(4 Suppl):S69-72. PubMed ID: 25268599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis.
    Boy MG; Wang C; Wilkinson BE; Chow VF; Clucas AT; Krueger JG; Gaweco AS; Zwillich SH; Changelian PS; Chan G
    J Invest Dermatol; 2009 Sep; 129(9):2299-302. PubMed ID: 19225543
    [No Abstract]   [Full Text] [Related]  

  • 39. Tofacitinib for the treatment of refractory Takayasu's arteritis: description of 2 cases.
    Palermo A; Marvisi C; Casali M; Pipitone N; Muratore F; Salvarani C
    Clin Exp Rheumatol; 2020; 38 Suppl 124(2):234-235. PubMed ID: 31928593
    [No Abstract]   [Full Text] [Related]  

  • 40. Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis.
    Castelo-Soccio L
    J Am Acad Dermatol; 2017 Apr; 76(4):754-755. PubMed ID: 28325392
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.